Group 1 - The company will implement a cash dividend distribution of 0.73 yuan per 10 shares, totaling approximately 10.05 million yuan, which represents 13.92% of the net profit attributable to shareholders [1][2] - The company's total share capital is 140,363,220 shares, with 2,730,914 shares repurchased, affecting the calculation of the dividend distribution [1][2] - The dividend distribution plan was approved at the annual shareholders' meeting on May 7, 2025, and further details can be found in the announcement dated April 16, 2025 [1][2] Group 2 - The convertible bonds will undergo a price adjustment in accordance with the terms outlined in the bond issuance prospectus following the dividend distribution [2] - The trading of the convertible bonds will be suspended from June 24, 2025, until the registration date for the dividend distribution, with resumption of trading on the first trading day after the registration date [2] - Investors interested in the details of the convertible bonds can refer to the prospectus disclosed on June 24, 2022 [2]

证券代码：688026 证券简称：洁特生物 公告编号：2025-034 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 关于实施 2024 年年度权益分派时可转债转股价格调整 暨转股连续停牌的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施 2024 年年度权益分派，本公司的相关证券停复牌情况如下：权益分派 公告前一交易日（2025 年 6 月 24 日）至权益分派股权登记日期间，本公司可转债 将停止转股。 | | | 一、2024 年度权益分派方案的基本情况 广州洁特生物过滤股份有限公司（以下简称"公司"）2024 年度利润分配方案 为：以实施权益分派股权登记日登记的总股本扣除公司回购专户已回购股份后的 股份余额为基数，向全体股东每 10 股派发现金红利 0.73 元（含税）。截至利润分 配预案公告披露日，公司总股本 140,363,220 股，扣除回购专户的股份 2,730,914 股，以此计算合计拟派发现金红利 10,047,158.34 ...

Group 1 - The company will suspend the conversion of its convertible bonds from June 24, 2025, until the equity distribution record date, with conversion resuming on the first trading day after the record date [1] - The cash dividend plan for the fiscal year 2024 includes a distribution of 0.73 yuan (tax included) for every 10 shares held, amounting to a total cash dividend of 10.0472 million yuan (tax included) [1]

Core Viewpoint - The announcement from Jiet Bio (688026.SH) regarding a share reduction plan by its shareholder, Guangzhou Luogang District Huizi Investment Management Partnership, indicates a planned reduction of up to 186,315 shares, representing no more than 0.1327% of the company's total share capital, due to the shareholder's personal funding needs [1][2]. Group 1: Shareholder Reduction Plan - The shareholder, Huizi Investment, plans to reduce its holdings through centralized bidding from July 2, 2025, to October 1, 2025 [1][2]. - The total shares held by Huizi Investment before the reduction is 1,396,950 shares, which accounts for 1.00% of the company's total share capital [2]. - The shares intended for reduction were acquired before the IPO and through capital reserve conversion [2]. Group 2: Company Background - Jiet Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 22, 2020, with an issuance of 25 million shares at a price of 16.49 yuan per share [3]. - The company raised a total of 412.25 million yuan from its initial public offering, with a net amount of 379.41 million yuan after deducting issuance costs [3][5]. - The company has conducted two fundraising activities, totaling 852.25 million yuan [5]. Group 3: Financial Information - The company issued convertible bonds approved by the China Securities Regulatory Commission, raising a total of 440 million yuan, with a net amount of approximately 432.49 million yuan after expenses [4]. - The company distributed cash dividends of 0.6 yuan per share and increased its capital stock by 0.4 shares per share based on a total share capital of 100 million shares prior to the distribution [6].

Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Guangzhou Jiete Biological Filtration Co., Ltd., indicating a planned sale of shares due to personal financial needs, while ensuring that this action will not affect the company's control or governance structure [2][3][7]. Group 1: Shareholder Information - The shareholder, Guangzhou Luogang District Huizi Investment Management Partnership (Limited Partnership), holds 1,396,950 shares, representing 1.00% of the company's total equity [2]. - The shares were acquired prior to the company's IPO and became tradable on January 30, 2023, after the lifting of restrictions [2]. Group 2: Reduction Plan Details - The shareholder plans to reduce their holdings by up to 186,315 shares, which is approximately 0.1327% of the total equity, within a three-month period starting from July 2, 2025, to October 1, 2025 [3]. - The reduction will be executed through centralized bidding, and any changes in the company's share structure during this period will lead to adjustments in the reduction plan [3]. Group 3: Control and Governance Impact - The reduction plan will not lead to a change in the company's control, as the shareholder is an associated party of the controlling shareholder, ensuring that governance and operational continuity remain unaffected [3][7]. - The actual controller's family member, Wang Jing, will not reduce her indirect holdings through the investment partnership, further stabilizing the control structure [3][7]. Group 4: Previous Commitments - The shareholder has previously committed not to transfer or manage shares held prior to the IPO for a period of 12 months post-listing, which aligns with the current reduction plan [5][6]. - Wang Jing has also made commitments regarding the management of her shares, including restrictions on transfer during specific periods [6].

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 证券代码：688026 证券简称：洁特生物 公告编号：2025-033 重要内容提示： ? 股东持有的基本情况 本次减持计划实施前，股东广州萝岗区汇资投资管理合伙企业（有限合伙） （以下简称"汇资投资"）持有广州洁特生物过滤股份有限公司（以下简称"公司"） 股份 1,396,950 股，占公司总股本 1.00%。上述股份来源为公司 IPO 前取得的及 通过资本公积转增股本取得的股份，已于 2023 年 1 月 30 日解除限售并上市流通。 ? 减持计划的主要内容 因股东自身资金需求，汇资投资拟于减持计划披露之日起 15 个交易日后的 份数量不超过 186,315 股，减持比例不超过公司总股本的 0.1327%。若公司在上 述减持计划实施期间发生送股、转增股本、增发新股股份变动事项，则上述减持 计划将作出相应调整。 汇资投资普通合伙人、执行事务合伙人王婧为公司实际控制人 Yuan Ye Jam ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-033 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次减持计划实施前，股东广州萝岗区汇资投资管理合伙企业（有限合伙） （以下简称"汇资投资"）持有广州洁特生物过滤股份有限公司（以下简称"公司"） 股份 1,396,950 股，占公司总股本 1.00%。上述股份来源为公司 IPO 前取得的及 通过资本公积转增股本取得的股份，已于 2023 年 1 月 30 日解除限售并上市流通。 减持计划的主要内容 因股东自身资金需求，汇资投资拟于减持计划披露之日起 15 个交易日后的 3 个月内（即 2025 年 7 月 2 日至 2025 年 10 月 1 日）通过集中竞价方式减持股 份数量不超过 186,315 股，减持比例不超过公司总股本的 0.132 ...

洁特生物公告，因股东自身资金需求，汇资投资拟于2025年7月2日至2025年10月1日期间，通过集中竞 价方式减持不超过18.63万股，占公司总股本的0.1327%。 ...

Core Viewpoint - The company has reached a settlement in a legal dispute involving its wholly-owned subsidiary, which will positively impact its financial position by recovering a significant amount of previously written-off bad debts [2][11]. Summary by Sections Legal Proceedings Overview - The lawsuit involves Guangzhou Jiete Biological Filtration Co., Ltd.'s subsidiary, Guangzhou Baifeier Air Purification Materials Co., Ltd., as the plaintiff in a contract dispute with Shandong Dayong New Materials Co., Ltd. [2][4]. - The total amount involved in the case is approximately 10,866,391.80 yuan, excluding additional costs [3]. Settlement Agreement - A settlement agreement was reached where Shandong Dayong will pay 6,470,000 yuan to Baifeier, covering all related costs and fees [11]. - The agreement stipulates that both parties will not pursue any further claims against each other regarding this dispute [11][12]. Financial Impact - The company had previously made provisions for bad debts amounting to 7,533,582.08 yuan related to this case, which will now be reversed following the settlement [12]. - The company also recorded a provision for inventory depreciation of 3,208,618.86 yuan for PTFE composite mask non-woven fabric [12]. Future Actions - Following the receipt of the settlement amount, the company will apply to withdraw its legal claims and terminate the execution of the contract dispute [11][12].

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-032 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于子公司诉讼事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次诉讼的基本情况 公司全资子公司拜费尔与山东大荣分别于 2020 年 3 月 13 日、2020 年 4 月 6 日、2020 年 4 月 14 日签订了三份关于 PTFE 复合口罩无纺布的《销售合同》（以 下合称"《销售合同》"），2021 年拜费尔就《销售合同》纠纷一案向法院提 起诉讼，具体内容详见公司于 2021 年 7 月 16 日披露的《关于子公司提起诉讼的 1 1、 案件所处的诉讼阶段：和解结案 2、 上市公司所处的当事人地位：广州洁特生物过滤股份有限公司（以下简称 "公司"）全资子公司广州拜费尔空气净化材料有限公司（以下简称"拜 费尔"）为（2024）粤民申 2817 号案件再审申请人（一审原告， ...